Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 août 2024 08h00 HE | Palisade Bio, Inc.
Carlsbad, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
13 août 2024 08h05 HE | Palisade Bio, Inc.
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Company continues to...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
08 août 2024 08h00 HE | Palisade Bio, Inc.
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Participates in Virtual Investor “What this Means” Segment
31 juil. 2024 09h15 HE | Palisade Bio, Inc.
Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108 Carlsbad, CA, July 31, 2024 ...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
29 juil. 2024 08h30 HE | Palisade Bio, Inc.
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
24 juin 2024 09h00 HE | Palisade Bio, Inc.
Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio to Present at the Virtual Investor Pitch Conference
10 juin 2024 09h15 HE | Palisade Bio, Inc.
Live video webcast on Monday, June 17th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical...
Picture1
Palisade Bio Appoints Margery Fischbein to its Board of Directors
07 mai 2024 08h30 HE | Palisade Bio, Inc.
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May ...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
07 mai 2024 07h30 HE | Palisade Bio, Inc.
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
02 mai 2024 08h30 HE | Palisade Bio, Inc.
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...